Neostigmine is a potent reversible cholinesterase inhibitor used in medical practice for various conditions. Primarily, it is indicated for the symptomatic treatment of myasthenia gravis, an autoimmune neuromuscular disorder characterized by muscle weakness. It works by inhibiting the enzyme acetylcholinesterase, which breaks down acetylcholine, thereby increasing the concentration of acetylcholine at the neuromuscular junction and enhancing muscle contraction. Neostigmine is also employed to reverse the effects of non-depolarizing neuromuscular blocking agents following surgery. This product, supplied as ampoules, provides a sterile solution for parenteral administration (intramuscular, intravenous, or subcutaneous), allowing for precise dosing and rapid onset of action crucial in acute management and diagnostic procedures. Each ampoule contains a specific strength, typically 0.5 mg/mL, for controlled administration.